share_log

Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49

Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49

富國銀行將Integra Lifesciences上調至增持,將目標股價提高至49美元
Benzinga ·  2023/12/05 06:01

Wells Fargo analyst Larry Biegelsen upgrades Integra Lifesciences (NASDAQ:IART) from Equal-Weight to Overweight and raises the price target from $40 to $49.

富國銀行分析師拉里·比格爾森將Integra Lifesciences(納斯達克股票代碼:IART)從等權重上調至增持,並將目標股價從40美元上調至49美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論